Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 10/20 | 0.53 |
| ▸ | CYP1A1 | P04798 | 9/20 | 0.53 |
| ▸ | CYP1B1 | Q16678 | 9/20 | 0.53 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.38 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.38 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.38 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5204984 | 1.00 | CYP1A2 (0.53) | CYP1A2CYP1A1CYP1B1PTGS2PTGS1 | |
| SCHEMBL5865323 | 0.86 | TP53 (0.36) | CYP1A2CYP1A1CYP1B1PTGS2PTGS1 | |
| SCHEMBL5865321 | 0.86 | TP53 (0.36) | CYP1A2CYP1A1CYP1B1PTGS2PTGS1 | |
| SCHEMBL5202329 | 0.83 | PTGS2 (0.48) | PTGS2PTGS1 | |
| SCHEMBL5865334 | 0.83 | PTGS2 (0.48) | PTGS2PTGS1 | |
| SCHEMBL5204715 | 0.80 | PTGS2 (0.58) | CYP1A2PTGS2PTGS1CYP3A4CYP2C9 | |
| SCHEMBL6885231 | 0.80 | PTGS2 (0.58) | CYP1A2PTGS2PTGS1CYP3A4CYP2C9 | |
| SCHEMBL5205097 | 0.73 | GABRP (0.43) | CYP1A2CYP1A1CYP1B1PTGS2PTGS1 | |
| SCHEMBL5796056 | 0.73 | CYP1A2 (1.00) | CYP1A2CYP1A1CYP1B1PTGS2KDM4E | |
| SCHEMBL6132473 | 0.70 | PTGS2 (0.67) | CYP1A2PTGS2PTGS1SMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1539718-A4 | 1,2,4-TRIAZOLE DERIVATIVE, METHOD FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | CJ CORP (KR) | 2007-08-01 | — | — | EP | disclosed |
| US-7019144-B2 | 1,2,4-Triazole derivative, method for preparing the same, and pharmaceutical composition containing the same | CJ CORP. (KR) | 2006-03-28 | — | — | US | disclosed |
| EP-1539718-A1 | 1,2,4-TRIAZOLE DERIVATIVE, METHOD FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | CJ Corporation (KR) | 2005-06-15 | — | — | EP | disclosed |
| US-20050075507-A1 | 1,2,4-Triazole derivative, method for preparing the same, and pharmaceutical composition containing the same | CJ CHEILJEDANG CORPORATION (KR) | 2005-04-07 | — | — | US | disclosed |
| WO-2004014878-A1 | 1,2,4-TRIAZOLE DERIVATIVE, METHOD FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | CJ CORPORATION (KR) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075507-A1 | 1,2,4-Triazole derivative, method for preparing the same, and pharmaceutical composition containing the same | CYP4B1, CYP3A5, CYP7A1 | CYP1A2 11/4885CYP1A1 15/4885CYP1B1 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.